ArticleJournal of pharmacy & bioallied sciences2025
A Systematic Review on the Effectiveness of Photodynamic Therapy in the Treatment of Oral Precancerous Lesions and Oral Cancers.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photodynamic therapy (PDT) has gained prominence as a minimally invasive treatment for various oral precancerous lesions and cancers, offering a targeted therapeutic approach with limited side effects. Among the commonly used photosensitizers, 5-aminolevulinic acid (ALA) has shown promise when activated by specific light sources. A comprehensive review of the literature was conducted, focusing on studies that utilized ALA-PDT for oral potentially malignant disorders (OPMDs) and early-stage oral cancers. Key data were extracted, including lesion type, number of treatment sessions, light power density, side effects, and recurrence rates. Comparative analysis was performed to identify consistent trends and variations across different lesion types. The review included data from 11 studies. Oral verrucous hyperplasia (OVH) and oral erythroleukoplakia (OEL) were found to respond favorably to fewer than seven weekly ALA-PDT sessions. Oral leukoplakia demonstrated better outcomes with twice-weekly treatments. Additionally, methylene blue-mediated PDT showed marked improvement in oral lichen planus, with no reported adverse effects. While overall efficacy and safety were confirmed, inconsistencies emerged regarding optimal laser power density and recurrence risks, underscoring the need for individualized protocols. In conclusion, ALA-PDT appears to be an effective and well-tolerated treatment for several oral precancerous lesions. Lesion-specific characteristics and treatment parameters play a critical role in achieving complete regression. Standardized guidelines and further research are warranted to refine PDT protocols and enhance clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.